Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

268
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
268
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

207
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
207

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pemetrexed potentiates γδ T cell-based immunotherapy in NSCLC through ATM-STING-NF-κB-mediated induction of NKG2D ligands.

International immunopharmacology·2026
Same author

Restoring the powerhouse: mitochondrial transplantation in regenerative medicine and cancer therapy.

Nanoscale·2026
Same author

Finerenone Exposure and Ischemic Stroke in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Propensity Score-Matched Cohort Study.

Clinical medicine (London, England)·2026
Same author

Smoking-associated modulation of gut microbiota shapes response to immune checkpoint inhibitors in non-small cell lung cancer.

Cancer immunology, immunotherapy : CII·2026
Same author

Gut microbiome signatures discriminate deep vein thrombosis through machine learning and metabolic analysis.

Scientific reports·2026
Same author

Epidemiology of diagnosed inflammatory bowel disease in Taiwan population from 2011 to 2021: a population-based study.

BMC gastroenterology·2026

Related Experiment Video

Updated: Jun 27, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.8K

Thiazolidinediones Decrease the Recurrence of Intracerebral Hemorrhage in Type 2 Diabetes Mellitus Patients: A Nested

Cheng-Di Chiu1,2,3,4, You-Pen Chiu5,6, Hei-Tung Yip5,7

  • 1School of Medicine, China Medical University, Taichung, Taiwan, cdchiu4046@gmail.com.

Neuroepidemiology
|May 5, 2024
PubMed
Summary

Thiazolidinediones (TZDs) use in type 2 diabetes mellitus patients after intracerebral hemorrhage (ICH) is linked to reduced risks of major adverse cardiovascular events (MACEs), particularly hemorrhagic stroke (HS). This study highlights TZDs

Keywords:
Cardiovascular riskRecurrent hemorrhagic strokeSpontaneous intracerebral hemorrhageThiazolidinedionesType 2 diabetes mellitus

More Related Videos

A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia
09:35

A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia

Published on: November 15, 2024

355
A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

3.8K

Related Experiment Videos

Last Updated: Jun 27, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.8K
A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia
09:35

A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia

Published on: November 15, 2024

355
A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

3.8K

Area of Science:

  • Cardiovascular Research
  • Neurology
  • Endocrinology

Background:

  • Preclinical studies suggest thiazolidinediones (TZDs) have therapeutic potential for intracerebral hemorrhage (ICH).
  • Investigating cerebrovascular and cardiovascular outcomes in type 2 diabetes mellitus (T2DM) patients post-ICH is crucial.
  • Understanding TZD effects in T2DM patients with ICH requires further clinical investigation.

Purpose of the Study:

  • To examine cerebrovascular and cardiovascular outcomes in T2DM patients following ICH.
  • To compare outcomes between TZD users and non-users after ICH.
  • To assess the association of TZD use with mortality and major adverse cardiovascular events (MACEs) post-ICH.

Main Methods:

  • Retrospective nested case-control study utilizing the Taiwan National Health Insurance Research Database.
  • Included 62,515 T2DM patients hospitalized with ICH, with 7,603 TZD users.
  • Propensity score matching used to compare TZD users and non-users; primary outcomes were death and MACEs (ischemic stroke, hemorrhagic stroke, myocardial infarction, heart failure).

Main Results:

  • TZD users showed significantly lower MACE risks post-ICH (aHR: 0.90, 95% CI: 0.85-0.94).
  • A notable reduction in hemorrhagic stroke (HS) incidence was observed in TZD users, especially within the first 3 months post-ICH.
  • Specific aHR for HS: 0.74 (within 1 month) and 0.68 (1-3 months) post-ICH.

Conclusions:

  • TZD use in T2DM patients with ICH is associated with a reduced risk of subsequent hemorrhagic stroke (HS).
  • TZD therapy may lower the risk of mortality following intracerebral hemorrhage (ICH) in T2DM patients.
  • Findings support the potential benefit of TZDs in managing cardiovascular and cerebrovascular risks post-ICH.